Moonwalk Biosciences raises $57 million today to pursue epigenome engineering

blonca9
Jan 4, 2024
1 min read

Co-Founder and CEO Alex Aravanis describes how epigenetic engineering could have advantages over gene editing and why he thinks Moonwalk's 'complete view' of the epigenome could give it an edge in this space.

Recent Posts

See All

AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences

Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited

BIO International 2025: Sweden's Alligator has a phase three ready CD40 asset for pancreatic cancer and is looking for a partner to move it forward

Moonwalk Biosciences raises $57 million today to pursue epigenome engineering

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight